Tiziana Life Sciences (NASDAQ:TLSA – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Insider and Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Tiziana Life Sciences and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tiziana Life Sciences | N/A | N/A | N/A |
| Tectonic Therapeutic | N/A | -27.11% | -25.88% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tiziana Life Sciences | 1 | 0 | 0 | 0 | 1.00 |
| Tectonic Therapeutic | 1 | 0 | 5 | 1 | 2.86 |
Tectonic Therapeutic has a consensus price target of $81.50, indicating a potential upside of 270.29%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Tiziana Life Sciences.
Risk & Volatility
Tiziana Life Sciences has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.71, suggesting that its stock price is 271% more volatile than the S&P 500.
Valuation and Earnings
This table compares Tiziana Life Sciences and Tectonic Therapeutic”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tiziana Life Sciences | N/A | N/A | -$11.86 million | N/A | N/A |
| Tectonic Therapeutic | N/A | N/A | -$57.98 million | ($3.86) | -5.70 |
Summary
Tectonic Therapeutic beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.
About Tiziana Life Sciences
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
